The text addresses the phenomenon of "Ozempic face," a condition where individuals using GLP-1 agonists such as Ozempic, Mounjaro, or Zepbound experience significant weight loss, which can lead to facial volume depletion and skin sagging. It outlines various aesthetic interventions available to mitigate these effects. For restoring lost facial volume, options include traditional hyaluronic acid fillers, newer fillers designed to stimulate the body's own fat production, and platelet-rich plasma (PRP) derived from the patient's blood. To combat skin laxity and sagging, non-surgical approaches are suggested, utilizing radiofrequency devices and ultrasound devices for skin tightening. These methods aim to help individuals maintain a more youthful facial appearance while benefiting from weight loss medications.